Drugs / Zr-Df-IAB22M2C
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04180215 | Dec 2019 → Jan 2025 | human papillomavirus-related squamous cell carcinoma | Hookipa Biotech GmbH | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2019-10-07 | ImaginAb, Inc. | Results ImaginAb Announces Publication of Data on First-In-Human Imaging in Patients with Solid Malignancies in The Journal of Nuclear Medicine imaginab.com ↗
The data from the Phase I trial reported in the paper demonstrated 89 Zr-Df-IAB22M2C was well tolerated with no immediate or delayed side effects observed. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2019-10-07 | ImaginAb, Inc. | ImaginAb Announces Publication of Data on First-In-Human Imaging in Patients with Solid Malignancies in The Journal of Nuclear Medicine imaginab.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Zr-Df-IAB22M2C | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04180215 ↗ |
| Modality | Diagnostic / imaging agent | “CD8 PET Tracer (Zr-Df-IAB22M2C)” NCT04180215 ↗ |